Big dealsOct 30, 2026
Viatris's $1.65 billion Pacira offer shows how long a signed deal takes to close
The agreement was signed October 8. The tender offer opened October 30 and runs to November 16 unless extended, with closing expected by the end of the month.
Deal at a glance
PendingPaid in: Cash- Buyer
- Viatris
- Target
- Pacira BioSciences
- Deal value
- $1.65B
- Equity value
- Announced
- Oct 2026
- Expected close
- End of November 2026
Figures are as stated by the companies, in US dollars. A deal can change or fall through before it closes.
Viatris's quarterly filing describes its agreement to buy Pacira BioSciences. The merger agreement was signed on October 8, 2026, at $36.50 per share in cash, an aggregate equity value of $1.65 billion.
The deal is structured as a tender offer. Viatris began the offer on October 30. It expires one minute after 11:59 p.m. Eastern on November 16 unless it is extended or ended earlier. If enough shares are tendered, Viatris plans a second step that acquires the remaining shares at the same $36.50 price.
Viatris says it will pay mainly from excess cash, with the remainder from short-term borrowings. Closing is expected by the end of November. The conditions include a majority of Pacira's shares being tendered and the end of the applicable regulatory waiting period. The filing says both boards approved the deal unanimously.
As of this note the offer had not closed, so treat it as pending.
Sources
We wrote this story ourselves from the sources below. Open them for the full text and exact wording.
This is a reading of public information, not investment, legal or tax advice. If a figure here is wrong, tell us and we will correct it.